XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Related Party Transactions
 3 Months Ended
Mar. 31, 2024
Related Party Transactions [Abstract]  
Related Party Transactions

12. Related Party Transactions

As of March 31, 2024 and December 31, 2023, the Company was obligated to pay Amgen $6.3 million and $3.1 million, respectively, under the Amgen Collaboration Agreement, which was recorded within current liabilities on the condensed consolidated balance sheets. As of March 31, 2024 and December 31, 2023, $9.4 million and $6.3 million, related to amounts prepayable to Amgen were recorded as prepaid expenses and other current assets on the condensed consolidated balance sheets. During the three months ended March 31, 2024 and 2023, the Company recorded nil and $8.1 million, respectively, of research and development expenses with Amgen.